Drug intelligence / Profile preview

CoV2 preS dTM + AS03

Development stage
Phase 2
Lead developer
Sanofi Pasteur
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**CoV2 preS dTM + AS03** is a recombinant protein subunit vaccine for prevention of COVID-19. It combines a recombinant prefusion-stabilized spike protein (preS dTM) of SARS-CoV-2, produced using a baculovirus expression vector system in insect cells, with AS03, a proprietary oil-in-water adjuvant composed of α-tocopherol, squalene, and polysorbate 80. The preS dTM protein is designed for increased stability and immunogenicity through specific mutations (including proline substitutions and deletion of the transmembrane domain with addition of a T4 foldon trimerization domain). AS03 enhances immune responses, promoting both neutralizing antibody production and cellular immune activation against spike protein, with demonstrated protection in animal models and humans. CoV2 preS dTM + AS03 has been evaluated in clinical trials for efficacy, safety, and immunogenicity as a primary immunization and booster against COVID-19, and is manufactured in both monovalent (ancestral and variant B.1.351 spike) and bivalent formulations[1][2][3][4].

Brand names
VidPrevtyn Beta
Other names
SARS-CoV-2 Spike Protein Vaccine adjuvanted with AS03SARS-CoV2 Spike Protein Vaccine adjuvanted with AS03SARS-CoV 2 Spike Protein Vaccine adjuvanted with AS03CoV2 preS dTM + AS03
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on CoV2 preS dTM + AS03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoV2 preS dTM + AS03.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call